Protective mechanisms of IVIG

Current Opinion in Immunology

Volumn 19, Issue 6, 2007, Pages 646-651

  Clynes, Raphael ^a  

^a Departments of Medicine and Microbiology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; IMMUNOGLOBULIN;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNITY; CELL ACTIVATION; DENDRITIC CELL; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNITY; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; MONOCYTE; MUCOCUTANEOUS LYMPH NODE SYNDROME; REVIEW; THERAPY EFFECT; TREATMENT INDICATION;

ANIMALS; ANTIGENS, CD; AUTOIMMUNITY; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSION; MICE; MONOCYTES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECEPTORS, IGG;

EID: 36849050907     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coi.2007.09.004     Document Type: Review

References (59)

1. Kazatchkine M.D., and Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. New Engl J Med 345 (2001) 747
2. Gold R., Stangel M., and Dalakas M.C. Drug insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 (2007) 36
3. Imbach P., Barandun S., d'Apuzzo V., Baumgartner C., Hirt A., Morell A., Rossi E., Schoni M., Vest M., and Wagner H.P. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1 (1981) 1228
4. Blanchette V., Imbach P., Andrew M., Adams M., McMillan J., Wang E., Milner R., Ali K., Barnard D., and Bernstein M. Randomised trial of intravenous immunoglobulin G, intravenous anti-D, and oral prednisone in childhood acute immune thrombocytopenic purpura [see comment]. Lancet 344 (1994) 703
5. Bierling P., and Godeau B. Intravenous immunoglobulin for autoimmune thrombocytopenic purpura. Human Immunol 66 (2005) 387
6. Bruhns P., Samuelsson A., Pollard J.W., and Ravetch J.V. Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18 (2003) 573. Identification of two distinct cells (sensor cells and effector cells) responsible for IVIG protection in an arthritis model.
7. Achiron A., Margalit R., Hershkoviz R., Markovits D., Reshef T., Melamed E., Cohen I.R., and Lider O. Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest 93 (1994) 600
8. Kaneko Y., Nimmerjahn F., Madaio M.P., and Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789
9. Inoue Y., Kaifu T., Sugahara-Tobinai A., Nakamura A., Miyazaki J., and Takai T. Activating Fc gamma receptors participate in the development of autoimmune diabetes in NOD mice. J Immunol 179 (2007) 764
10. Li N., Zhao M., Hilario-Vargas J., Prisayanh P., Warren S., Diaz L.A., Roopenian D.C., and Liu Z. Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115 (2005) 3440. Evidence for FcRn involvement in IVIG efficacy.
11. Heyns A.D., Lotter M.G., Badenhorst P.N., de Kock F., Pieters H., Herbst C., van Reenen O.R., Kotze H., and Minnaar P.C. Kinetics and sites of destruction of 111Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. Am J Hematol 12 (1982) 167
12. Clynes R., and Ravetch J.V. Cytotoxic antibodies trigger inflammation through Fc receptors. Immunity 3 (1995) 21
13. Alves-Rosa F., Stanganelli C., Cabrera J., van Rooijen N., Palermo M.S., and Isturiz M.A. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96 (2000) 2834
14. Sylvestre D., Clynes R., Ma M., Warren H., Carroll M.C., and Ravetch J.V. Immunoglobulin G-mediated inflammatory responses develop normally in complement-deficient mice. J Exp Med 184 (1996) 2385
15. Nimmerjahn F., and Ravetch J.V. Divergent immunoglobulin g subclass activity through selective Fc receptor binding [see comment]. Science 310 (2005) 1510. The pro-inflammatory potency of specific IgG subclasses is elegantly explained by their relative affinities for activating and inhibitory FcγRs (A:I Index) and in particular, the activities of the IgG2a and 2b subclass are explained by their affinity for the newly identified murine FcγRIV in binding the IgG2a and 2b subclasses.
16. Shoenfeld Y., Rauova L., Gilburd B., Kvapil F., Goldberg I., Kopolovic J., Rovensky J., and Blank M. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotypic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Int Immunol 14 (2002) 1303
17. Buchwald B., Ahangari R., Weishaupt A., and Toyka K.V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome [see comment]. Annal Neurol 51 (2002) 673
18. Basta M., Van Goor F., Luccioli S., Billings E.M., Vortmeyer A.O., Baranyi L., Szebeni J., Alving C.R., Carroll M.C., Berkower I., et al. F(ab)'2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9 (2003) 431
19. Viard I., Wehrli P., Bullani R., Schneider P., Holler N., Salomon D., Hunziker T., Saurat J.H., Tschopp J., and French L.E. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282 (1998) 490
20. Bleeker W.K., Teeling J.L., and Hack C.E. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98 (2001) 3136
21. Scaradavou A., Woo B., Woloski B.M., Cunningham-Rundles S., Ettinger L.J., Aledort L.M., and Bussel J.B. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 89 (1997) 2689
22. Siragam V., Brinc D., Crow A.R., Song S., Freedman J., and Lazarus A.H. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease?[see comment]. J Clin Invest 115 (2005) 155. The inhibitory activity of IVIG in vivo is recapitulated here by immune complexes formed in vivo.
23. Fehr J., Hofmann V., and Kappeler U. Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. New Engl J Med 306 (1982) 1254. An early clinical trial that demonstrates efficacy of IVIG and suggests that reticulendothelial blockade is responsible by showing that antibody-mediated clearance is reduced by IVIG.
24. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor [see comment]. Science 291 (2001) 484. The importance of both activating FcRIII and the inhibitory FcRIIB is demonstrated here: Anti-human FcRIII antibodies block ITP in hFcRIII transgenic mice and FcRIIB deficient mice are not protected by IVIG.
25. Soubrane C., Tourani J.M., Andrieu J.M., Visonneau S., Beldjord K., Israel-Biet D., Mouawad R., Bussel J., Weil M., and Khayat D. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood 81 (1993) 15. Both references show that anti-human FcRIII Abs can reverse ITP in patients.
26. •].
27. Kimberly R.P., Salmon J.E., Bussel J.B., Crow M.K., and Hilgartner M.W. Modulation of mononuclear phagocyte function by intravenous gamma-globulin. J Immunol 132 (1984) 745
28. Akilesh S., Petkova S., Sproule T.J., Shaffer D.J., Christianson G.J., and Roopenian D. The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. J Clin Invest 113 (2004) 1328
29. Hansen R.J., and Balthasar J.P. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia [see comment]. Blood 100 (2002) 2087
30. Deng R., and Balthasar J.P. Pharmacokinetic/pharmacodynamic modeling of IVIG effects in a murine model of immune thrombocytopenia. J Pharm Sci 96 (2007) 1625
31. Ravetch J.V., and Clynes R.A. Divergent roles for Fc receptors and complement in vivo. Annu Rev Immunol 16 (1998) 421
32. Desai D.D., Harbers S.O., Flores M., Colonna L., Downie M.P., Bergtold A., Jung S., and Clynes R. Fc gamma receptor IIB on dendritic cells enforces peripheral tolerance by inhibiting effector T cell responses. J Immunol 178 (2007) 6217
33. Diaz de Stahl T., Andren M., Martinsson P., Verbeek J.S., and Kleinau S. Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur J Immunol 32 (2002) 2915
34. Ioan-Facsinay A., de Kimpe S.J., Hellwig S.M., van Lent P.L., Hofhuis F.M., van Ojik H.H., Sedlik C., da Silveira S.A., Gerber J., de Jong Y.F., et al. FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection. Immunity 16 (2002) 391
35. Ji H., Ohmura K., Mahmood U., Lee D.M., Hofhuis F.M., Boackle S.A., Takahashi K., Holers V.M., Walport M., Gerard C., et al. Arthritis critically dependent on innate immune system players. Immunity 16 (2002) 157
36. Abdul-Majid K.B., Stefferl A., Bourquin C., Lassmann H., Linington C., Olsson T., Kleinau S., and Harris R.A. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand J Immunol 55 (2002) 70
37. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8 (2002) 500
38. Harbers S.O., Crocker A., Catalano G., D'Agati V., Jung S., Desai D.D., and Clynes R. Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117 (2007) 1361
39. Kaneko Y., Nimmerjahn F., Madaio M.P., and Ravetch J.V. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789
40. Crow A.R., Song S., Freedman J., Helgason C.D., Humphries R.K., Siminovitch K.A., and Lazarus A.H. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 102 (2003) 558
41. Siragam V., Crow A.R., Brinc D., Song S., Freedman J., and Lazarus A.H. Intravenous immunoglobulin ameliorates ITP via activating Fc gamma receptors on dendritic cells. Nat Med 12 (2006) 688. This study affirms the two-cell model of ITP efficacy and identifies an ITAM-mediated inhibitory pathway in splenic dendritic cells.
42. Bayry J., Lacroix-Desmazes S., Carbonneil C., Misra N., Donkova V., Pashov A., Chevailler A., Mouthon L., Weill B., Bruneval P., et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 101 (2003) 758. IVIG is shown to inhibit the allostimulatory capacity of human DCs and the LPS-induced maturation response.
43. Bayry J., Lacroix-Desmazes S., Delignat S., Mouthon L., Weill B., Kazatchkine M.D., and Kaveri S.V. Intravenous immunoglobulin abrogates dendritic cell differentiation induced by interferon-alpha present in serum from patients with systemic lupus erythematosus. Arthritis Rheum 48 (2003) 3497
44. Park-Min K.H., Serbina N.V., Yang W., Ma X., Krystal G., Neel B.G., Nutt S.L., Hu X., and Ivashkiv L.B. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26 (2007) 67. IVIG is shown to inhibit cellular immunity in a Listeria model and to inhibit IFN-γ responses in cultured monocytes via FcγRIII. Thus a link between and IVIG and cellular immunity is established.
45. Sutterwala F.S., Noel G.J., Clynes R., and Mosser D.M. Selective suppression of interleukin-12 induction after macrophage receptor ligation. J Exp Med 185 (1997) 1977
46. •], an inhibitory activity of activating FcR engagement is first noted.
47. Pasquier B., Launay P., Kanamaru Y., Moura I.C., Pfirsch S., Ruffie C., Henin D., Benhamou M., Pretolani M., Blank U., et al. Identification of FcalphaRI as an inhibitory receptor that controls inflammation: dual role of FcRgamma ITAM. Immunity 22 (2005) 31. Inhibitory signaling through FcRαRI is identified upon low valency cross-linking in a pathway involving SHP-1 and ERK.
48. Takahashi K., Rochford C.D., and Neumann H. Clearance of apoptotic neurons without inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med 201 (2005) 647
49. Blasius A.L., Cella M., Maldonado J., Takai T., and Colonna M. Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 107 (2006) 2474
50. Hamerman J.A., Tchao N.K., Lowell C.A., and Lanier L.L. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat Immunol 6 (2005) 579
51. Hamerman J.A., Jarjoura J.R., Humphrey M.B., Nakamura M.C., Seaman W.E., and Lanier L.L. Cutting edge: inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells (TREM)-2 and DAP12. J Immunol 177 (2006) 2051
52. Fuchs A., Cella M., Kondo T., and Colonna M. Paradoxic inhibition of human natural interferon-producing cells by the activating receptor NKp44. Blood 106 (2005) 2076
53. Ujike A., Takeda K., Nakamura A., Ebihara S., Akiyama K., and Takai T. Impaired dendritic cell maturation and increased T(H)2 responses in PIR-B(-/-) mice. Nat Immunol 3 (2002) 542
54. Cao W., Rosen D.B., Ito T., Bover L., Bao M., Watanabe G., Yao Z., Zhang L., Lanier L.L., and Liu Y.J. Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. J Exp Med 203 (2006) 1399
55. Hamerman JA, Lanier LL: Inhibition of immune responses by ITAM-bearing receptors. Science's Stke [Electronic Resource]: Signal Transduction Knowledge Environment 2006:re1.
56. Shields R.L., Lai J., Keck R., O'Connell L.Y., Hong K., Meng Y.G., Weikert S.H., and Presta L.G. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277 (2002) 26733
57. Umana P., Jean-Mairet J., Moudry R., Amstutz H., and Bailey J.E. Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17 (1999) 176
58. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670. This landmark study identifies a sialated component of IgG that has reduced affinity for FcγRs and is anti-inflammatory.
59. Crocker P.R., Paulson J.C., and Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol 7 (2007) 255